Lantern Pharma Inc (LTRN)

Jun 13, 2025

Lantern Pharma shares sold by major shareholder for $123,600 - Investing.com India

Jun 13, 2025

Jun 13, 2025

Lantern Pharma Inc. (NASDAQ:LTRN) Q1 2025 Earnings Call Transcript - MSN

Jun 13, 2025

Jun 13, 2025

Lantern Pharma sees $208,271 in stock sales by major shareholders - Investing.com India

Jun 13, 2025

Jun 13, 2025

Lantern Pharma (NASDAQ:LTRN) Trading Down 4.4% – Here’s Why - Defense World

Jun 13, 2025

Jun 12, 2025

Lantern Pharma Inc. Harnesses AI to Revolutionize Oncology Drug Development - citybuzz -

Jun 12, 2025

Jun 01, 2025

Lantern Pharma Inc. (LTRN)’s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models - MSN

Jun 01, 2025

May 31, 2025

Here's Why We're Watching Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation - Yahoo Finance

May 31, 2025

May 30, 2025

Lantern pharma investors see $168,418 in stock sales By Investing.com - Investing.com Nigeria

May 30, 2025

May 29, 2025

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials - BioSpace

May 29, 2025

May 29, 2025

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors at SNO Pediatric Conference - marketscreener.com

May 29, 2025

May 29, 2025

Lantern Pharma's LP-184 Shows Promise in Pediatric Brain Cancer | LTRN Stock News - GuruFocus

May 29, 2025

May 29, 2025

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atyp - GuruFocus

May 29, 2025

May 29, 2025

Lantern Pharma’s LP-184 shows promise for pediatric brain cancer - Investing.com

May 29, 2025

May 23, 2025

FY2025 EPS Forecast for Lantern Pharma Increased by Analyst - Defense World

May 23, 2025

May 22, 2025

Zacks Small Cap Estimates Lantern Pharma Q2 Earnings - Defense World

May 22, 2025

May 20, 2025

Lantern Pharma outlines commercialization of radar AI modules and expects LP-184 trial enrollment completion by June 2025 - MSN

May 20, 2025

May 19, 2025

LTRN: First Quarter 2025 Financial Results - Yahoo Finance

May 19, 2025

May 16, 2025

Lake Street to Host Virtual Meeting Featuring LTRN on May 20 | L - GuruFocus

May 16, 2025

May 16, 2025

Lantern Pharma Q1 2025 slides: narrowing losses as clinical trials advance - Investing.com Nigeria

May 16, 2025

May 16, 2025

Lantern Pharma Advances AI-Driven Cancer Therapies - TipRanks

May 16, 2025

May 15, 2025

Lantern Pharma’s Earnings Call: Progress and Prospects - TipRanks

May 15, 2025

May 15, 2025

Lantern Pharma Q1 2025 slides: narrowing losses as clinical trials advance By Investing.com - Investing.com South Africa

May 15, 2025

May 15, 2025

Transcript : Lantern Pharma Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com

May 15, 2025

May 15, 2025

Lantern Pharma Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:LTRN) - Seeking Alpha

May 15, 2025

May 15, 2025

Earnings call transcript: Lantern Pharma Q1 2025 reports narrower loss - Investing.com

May 15, 2025

May 15, 2025

Earnings call transcript: Lantern Pharma Q1 2025 reports narrower loss By Investing.com - Investing.com India

May 15, 2025

May 15, 2025

Lantern Pharma Q1 2025 Earnings Call Transcript - MarketBeat

May 15, 2025

May 15, 2025

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates | LTRN Stock News - GuruFocus

May 15, 2025

May 15, 2025

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates - BioSpace

May 15, 2025

May 15, 2025

Lantern Pharma Reports Q1 2025 Financial Results - TipRanks

May 15, 2025

May 15, 2025

Lantern Pharma Inc. SEC 10-Q Report - TradingView

May 15, 2025

May 14, 2025

Yaber Highlights the Timeless Design and Natural Aesthetic of the T2 Series in "Lunar Rock" Colorway - Barchart.com

May 14, 2025

May 14, 2025

Why Beat Earnings When You Can Just Buy The Dip? - Barchart.com

May 14, 2025

May 14, 2025

BIG ROCK BREWERY INC. ANNOUNCES FIRST QUARTER 2025 RESULTS AND 51% INCREASE IN SALES VOLUMES - Barchart.com

May 14, 2025

May 14, 2025

The Ordre des arts et des lettres du Québec announces its 2025 cohortTen luminaries will become honorary members on June 9 - Barchart.com

May 14, 2025

May 13, 2025

Abigail Disney Urges Donors To Be Braver About Their Giving And Shouldering More Risk - Barchart.com

May 13, 2025

May 13, 2025

STATEMENTWith New Federal Health Minister Installed, It's Time To Get To Work: CMA - Barchart.com

May 13, 2025

May 13, 2025

Henry Mauriss Calls For A New Era Of Entrepreneurial Innovation In Media - Barchart.com

May 13, 2025

May 13, 2025

Phyllis Waud and Rebecca Murray of Syntax Named to CRN's 2025 Women of the Channel List - Barchart.com

May 13, 2025

May 13, 2025

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Tria - GuruFocus

May 13, 2025

May 12, 2025

What Is Moving The Markets Now? - Barchart.com

May 12, 2025

May 12, 2025

Trump sets 30-day deadline for pharmaceutical companies to lower US drug prices in executive order - Barchart.com

May 12, 2025

May 12, 2025

Tino’s Tree Service VA Prioritizes Property Protection with Fully Insured, Expert-Guided Tree Solutions - Barchart.com

May 12, 2025

May 12, 2025

Lantern Pharma (LTRN) Gets FDA Clearance for Clinical Trial Targeting Treatment-Resistant, Genomically-Defined Lung Cancer with AI developed LP-184 - Barchart.com

May 12, 2025

May 12, 2025

FDA clears LP-184 trial for NSCLC patients with specific mutations - Investing.com Nigeria

May 12, 2025

May 12, 2025

FDA Clears Lantern Pharma's (LTRN) Clinical Trial Amendment for NSCLC Treatment | LTRN Stock News - GuruFocus

May 12, 2025

May 12, 2025

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need - NewsBreak: Local News & Alerts

May 12, 2025